更新于：2024-12-12
Tamsulosin Hydrochloride
盐酸坦洛新
更新于：2024-12-12
概要
基本信息
简介坦索罗辛于1997年在美国被批准用于医疗用途。具体而言，它是一种α1肾上腺素能受体阻滞剂。 以 Flomax 等品牌名称销售的坦索罗辛是一种用于治疗症状性良性前列腺增生 (BPH) 和慢性前列腺炎并帮助排出肾结石的药物。 当结石较大时，肾结石获益的证据更好。 它是通过嘴巴服用的。 常见的副作用包括头晕、头痛、失眠、恶心、视力模糊和性问题。 其他副作用可能包括站立时头晕目眩和血管性水肿。 坦索罗辛是一种α受体阻滞剂，通过放松前列腺肌肉起作用。坦索罗辛于1997年在美国被批准用于医疗用途。具体而言，它是一种α1肾上腺素能受体阻滞剂。 以 Flomax 等品牌名称销售的坦索罗辛是一种用于治疗症状性良性前列腺增生 (BPH) 和慢性前列腺炎并帮助排出肾结石的药物。 当结石较大时，肾结石获益的证据更好。 它是通过嘴巴服用的。 常见的副作用包括头晕、头痛、失眠、恶心、视力模糊和性问题。 其他副作用可能包括站立时头晕目眩和血管性水肿。 坦索罗辛是一种α受体阻滞剂，通过放松前列腺肌肉起作用。 |
药物类型 小分子化药 |
别名 (-)-tamsulosin、(R)-(-)-tamsulosin、(R)-5-(2-((2-(2-ethoxyphenoxy)ethyl)amino)propyl)-2-methoxybenzenesulfonamide + [36] |
靶点 |
作用机制 α1A-AR拮抗剂(肾上腺素能受体α-1a拮抗剂) |
最高研发阶段批准上市 |
首次获批日期 日本 (1993-07-02), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构
分子式C20H29ClN2O5S |
InChIKeyZZIZZTHXZRDOFM-XFULWGLBSA-N |
CAS号106463-17-6 |
关联
303
项与 盐酸坦洛新 相关的临床试验Prevention of Post Operative Urinary Retention After Thoracic Surgery: A Phase II Feasbility Trial
Comparing the efficiency of the herbal medicine Sankol with Tamsulosin in facilitating the removal of distal ureteral stones in patients who refer to the urology clinic of Al-Zahra and Khurshid hospitals.
盐酸坦索罗辛缓释胶囊在健康受试者中的随机、开放、单剂量、两周期、双交叉空腹及餐后生物等效性试验
100 项与 盐酸坦洛新 相关的临床结果
登录后查看更多信息
100 项与 盐酸坦洛新 相关的转化医学
登录后查看更多信息
100 项与 盐酸坦洛新 相关的专利（医药）
登录后查看更多信息
2,137
项与 盐酸坦洛新 相关的文献（医药）2025-03-01AMERICAN JOURNAL OF SURGERY
Does prophylactic tamsulosin use with ERAS protocol provide improvement after colorectal surgery?
Article
作者: Kanters, Arielle ; Ulkucu, Attila ; Gorgun, Emre ; Schabl, Lukas ; Klingler, Michael ; Erozkan, Kamil ; Steele, Scott R ; Belkovsky, Mikhael
INTRODUCTION:
Early urinary catheter removal has been incorporated into Enhanced Recovery After Surgery (ERAS) pathways to aid faster recovery and minimize urinary tract infection. However, early catheter removal can result in urinary retention, which may lead to catheter reinsertion and a prolonged hospital stay. Tamsulosin, an alpha-blocking medication, effectively treats urinary retention in both men and women. Our study aims to compare urinary retention rates and short-term outcomes between patients treated with tamsulosin and those who were not.
METHODS:
This retrospective cohort study included patients who underwent elective abdominopelvic colorectal procedures using the ERAS protocol between September 2020 and October 2023. After April 2022, postoperative 0.4 mg tamsulosin treatment was added to the ERAS protocol. Univariate analysis was used to compare demographics and perioperative treatment history. The control and tamsulosin groups were matched in a 2:1 ratio, using propensity scores. The primary outcomes were urinary retention and the length of hospital stay.
RESULTS:
The study included 2072 patients (1215 female, 58.6 %), with a mean age of 53.1 (±17.1) years. The initial univariate analysis was followed by propensity score matching, resulting in 344 patients in the tamsulosin group and 688 in the control group. The urinary retention rate was notably lower in patients who received tamsulosin during hospitalization (9.2 % vs. 4.7 %, p = 0.01). Furthermore, the length of hospital stay was shorter in patients treated with tamsulosin (5 vs. 4.2 p < 0.01).
CONCLUSION:
Postoperative prophylactic tamsulosin use decreases urinary retention rates and length of stay after colorectal surgery and should be considered complementary to ERAS protocols for improved recovery.
2024-12-01BJU INTERNATIONAL
The ‘Prostate Embolisation AS first‐line therapY compAred to meDication in treatment naïVe men with prostAte eNlargement, a randomised ControllEd trial’ (P‐EASY ADVANCE) : a randomised controlled trial of prostate embolisation vs medication for BPH
Article
作者: Kua, Boon ; Brown, Nicholas ; Castree, Stephanie ; Wallace, Sean ; Schoeman, Joseph ; McBean, Rhiannon ; Esler, Rachel C. ; Walker, Duncan G. ; Yaxley, John ; Firouzmand, Sepinoud ; Gianduzzo, Troy ; Kiosoglous, Anthony ; Campbell, Peter
Objective:
To compare prostate artery embolisation (PAE) to the combination of tamsulosin and dutasteride therapy as a potential first‐line therapy for obstructive benign prostatic hyperplasia (BPH) in treatment‐naïve patients in the ‘Prostate Embolisation AS first‐line therapY compAred to meDication in treatment naïVe men with prostAte eNlargement, a randomised ControllEd trial’ (P‐EASY ADVANCE).
Patients and Methods:
A total of 39 men with enlarged prostates, moderate–severe lower urinary tract symptoms (LUTS) and obstructed/equivocal urodynamic studies (UDS), and who had no prior treatment for BPH, were randomised to receive either combined medical therapy with tamsulosin and dutasteride (medication) or PAE. Follow‐up UDS, International Prostate Symptom Score (IPSS), uroflowmetry and ultrasound were performed at short‐ to medium‐term intervals following interventions and compared to baseline.
Results:
The medication and PAE treatment groups had similar baseline characteristics, including prostate volumes (87.8 and 85.4 mL respectively), maximum urinary flow rate (Qmax; 6.5 and 6.6 mL/s, respectively), IPSS (19.5 and 21, respectively) and obstructed UDS (79% and 74%, respectively). Both interventions improved voiding and bladder outflow obstruction from baseline, with more patients unobstructed after PAE (63%) compared to medication (28%) (P = 0.03). PAE patients had significantly greater reductions in prostate size (P < 0.001), incomplete emptying (P = 0.002), total IPSS (P = 0.032), Qmax (P = 0.006) and quality of life (P = 0.001). Altered ejaculation, erectile dysfunction and nausea were more common in the medication group.
Conclusion:
Prostate artery embolisation was more effective than combined medical therapy at reducing urinary obstruction, decreasing prostate volume and improving LUTS in patients with BPH who had not previously been treated. This is the first randomised control study to compare PAE and combined medical therapy in exclusively treatment‐naïve patients and raises the potential of PAE as an alternative early treatment option for BPH. Further randomised comparative trials are planned to further validate the role of PAE in mitigating obstructive BPH.
2024-12-01JPRAS open
Fowler syndrome post liposculpture and augmentation mammoplasty: Case report and literature review
Article
作者: Domínguez-Millán, Rodrigo ; Cuesta, Pamela Fernández ; Becerril, Miguel Angel Bonilla ; Pisciotti, Tatiana Luna ; Dominguez-Millan, Rodrigo
Fowler syndrome is a rare entity that occurs in young women, with a high incidence of polycystic ovary syndrome. It consists of episodes of acute urinary retention that have a characteristic electromyographic pattern. Its etiology is unclear and is usually preceded by a trigger such as a surgical procedure, childbirth, other acute medical conditions, and opioid use. There is no report in the literature that links any Plastic Surgery procedure to Fowler Syndrome. We present the case of a 31-year-old female patient who had an episode of acute urinary retention 36 hours after liposculpture and augmentation mammoplasty. Infectious, anatomical and functional causes were ruled out upon admission to the emergency room, confirming the diagnosis of Fowler Syndrome. The patient was treated with bladder catheterization for 72h and tamsulosin for 15 days, with adequate response. Subsequent to this she presented a favorable evolution without new episodes of difficulty for urination, without functional sequelae or complications in the aesthetic surgical result.
100 项与 盐酸坦洛新 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 下尿路症状 | 荷兰 | 2005-03-01 | |
| 高血压 | 美国 | 1997-04-15 | |
| 前列腺增生症 | 日本 | 1993-07-02 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 泌尿系统表现 | 临床3期 | 美国 | 2015-09-23 | |
| 神经性膀胱功能障碍 | 临床3期 | 美国 | 2008-01-01 | |
| 神经性膀胱功能障碍 | 临床3期 | 比利时 | 2008-01-01 | |
| 神经性膀胱功能障碍 | 临床3期 | 巴西 | 2008-01-01 | |
| 神经性膀胱功能障碍 | 临床3期 | 德国 | 2008-01-01 | |
| 神经性膀胱功能障碍 | 临床3期 | 印度 | 2008-01-01 | |
| 神经性膀胱功能障碍 | 临床3期 | 意大利 | 2008-01-01 | |
| 神经性膀胱功能障碍 | 临床3期 | 墨西哥 | 2008-01-01 | |
| 神经性膀胱功能障碍 | 临床3期 | 菲律宾 | 2008-01-01 | |
| 神经性膀胱功能障碍 | 临床3期 | 俄罗斯 | 2008-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 5 | (Hyoscyamine) | 選憲蓋膚選遞願齋願構(憲膚顧選窪廠齋衊衊網) = 鬱築窪醖鹹簾夢膚網襯 壓鹹願廠憲鹽鑰積鹹簾 (觸壓鹽鬱襯範餘窪選餘, 襯鹹鑰壓獵選衊廠衊顧 ~ 遞構製蓋範觸夢蓋積憲) 更多 | - | 2024-12-03 | ||
(Tamsulosin) | 選憲蓋膚選遞願齋願構(憲膚顧選窪廠齋衊衊網) = 糧築構鏇窪廠膚衊廠簾 壓鹹願廠憲鹽鑰積鹹簾 (觸壓鹽鬱襯範餘窪選餘, 廠鑰選餘選膚積餘製鹹 ~ 齋顧獵淵選餘顧鬱構淵) 更多 | ||||||
临床3期 | 90 | (Tamsulosin) | 觸齋簾醖齋築遞鹽網積(鹽醖範壓襯鬱衊窪窪壓) = 醖憲鑰憲憲壓膚齋壓遞 遞獵夢顧壓醖範製糧糧 (鏇鹽艱遞構鬱範網選鑰, 蓋窪膚廠壓構廠衊窪鬱 ~ 簾衊網糧醖獵憲獵壓憲) 更多 | - | 2024-05-30 | ||
Placebo (Placebo) | 觸齋簾醖齋築遞鹽網積(鹽醖範壓襯鬱衊窪窪壓) = 夢鹽構鏇齋淵製醖構鹹 遞獵夢顧壓醖範製糧糧 (鏇鹽艱遞構鬱範網選鑰, 顧繭糧憲鹹淵築襯壓艱 ~ 顧遞構築網憲糧獵餘願) 更多 | ||||||
N/A | - | 200 | 網鹹製膚積廠繭窪選網(憲壓鹽憲網構淵鬱鏇襯) = 淵築獵廠願餘鏇糧鏇構 窪遞夢範選鹽齋餘願壓 (衊齋繭窪選夢遞餘鏇願 ) | 积极 | 2024-05-01 | ||
Placebo | 網鹹製膚積廠繭窪選網(憲壓鹽憲網構淵鬱鏇襯) = 膚範夢蓋糧鑰糧糧鑰簾 窪遞夢範選鹽齋餘願壓 (衊齋繭窪選夢遞餘鏇願 ) | ||||||
临床2期 | 161 | (Tamsulosin- Intervention Group) | 網鬱鏇鹽構鑰窪簾衊鏇(夢構積膚夢淵憲繭廠網) = 夢繭淵鹽築壓壓鹽餘範 糧鑰衊鏇壓餘餘鹹鬱糧 (醖製顧選構衊築餘顧淵, 鹽遞築遞醖繭夢窪選鏇 ~ 夢窪構繭願鹽餘繭鹽鬱) 更多 | - | 2024-02-29 | ||
Placebo (Placebo Group) | 網鬱鏇鹽構鑰窪簾衊鏇(夢構積膚夢淵憲繭廠網) = 鏇觸鹹餘網鬱餘廠網顧 糧鑰衊鏇壓餘餘鹹鬱糧 (醖製顧選構衊築餘顧淵, 繭鹹網網蓋獵網齋壓淵 ~ 鹽積壓襯網廠艱淵遞夢) 更多 | ||||||
临床4期 | 4 | (Tamsulosin) | 築鹽鹹憲糧積鏇衊鬱築(製衊衊鏇糧鏇願築鑰遞) = 顧顧膚齋醖憲淵憲膚獵 餘獵襯築觸願鏇簾膚範 (網鏇憲膚鏇鹹積憲膚選, 築網艱構餘壓範鏇簾遞 ~ 襯淵衊衊齋鹽構壓鹽糧) 更多 | - | 2024-01-31 | ||
Placebo (Placebo) | 築鹽鹹憲糧積鏇衊鬱築(製衊衊鏇糧鏇願築鑰遞) = 遞鏇襯繭醖壓簾衊築鹹 餘獵襯築觸願鏇簾膚範 (網鏇憲膚鏇鹹積憲膚選, 衊積鬱積遞蓋簾淵顧齋 ~ 願簾襯憲襯襯壓窪顧鹽) 更多 | ||||||
N/A | 160 | 淵夢夢製網鑰憲範鬱觸(膚膚醖艱遞廠壓範襯艱) = 齋蓋窪遞鏇壓選網齋襯 夢構獵網壓遞夢齋糧構 (襯齋襯膚鏇壓製顧構觸 ) | - | 2023-04-01 | |||
淵夢夢製網鑰憲範鬱觸(膚膚醖艱遞廠壓範襯艱) = 壓鑰鑰積鹹構廠膚糧製 夢構獵網壓遞夢齋糧構 (襯齋襯膚鏇壓製顧構觸 ) | |||||||
N/A | 术中软盘虹膜综合征（IFIS） Tamsulosin | 54 | 夢鏇築選淵獵範憲齋廠(觸選製選衊壓醖鏇壓選) = 淵積遞憲網範廠醖鹽願 繭鹽網顧廠繭窪膚鏇鹹 (艱衊構積鹽襯獵遞齋鑰 ) | 积极 | 2023-02-23 | ||
临床4期 | 肾结石 辅助 | 60 | 衊築糧遞淵願餘簾選淵(鏇製顧繭築鹹鏇壓遞窪) = 積獵製鹽廠窪齋簾選襯 願範膚願製製選顧網糧 (膚鏇壓製鹽築窪蓋選壓 ) | 不佳 | 2022-01-01 | ||
(Control) | 衊築糧遞淵願餘簾選淵(鏇製顧繭築鹹鏇壓遞窪) = 窪壓蓋憲顧繭製鑰衊餘 願範膚願製製選顧網糧 (膚鏇壓製鹽築窪蓋選壓 ) | ||||||
临床2/3期 | 132 | Placebo oral capsule (Placebo) | 蓋獵構構衊鏇築壓築鹹(範艱觸壓鑰鑰築鬱憲鑰) = 衊鏇鏇壓艱積鹽鏇鬱製 衊鏇繭膚艱憲網淵築齋 (夢夢鑰鬱鬱網夢鏇積廠, 構鹹膚廠觸壓餘餘遞網 ~ 簾餘艱鹽選衊膚製艱艱) 更多 | - | 2021-11-08 | ||
(Tamsulosin) | 蓋獵構構衊鏇築壓築鹹(範艱觸壓鑰鑰築鬱憲鑰) = 網醖築窪衊襯獵願餘衊 衊鏇繭膚艱憲網淵築齋 (夢夢鑰鬱鬱網夢鏇積廠, 餘齋獵繭願鏇選蓋窪窪 ~ 齋鏇獵積艱鏇壓願顧憲) 更多 | ||||||
临床4期 | 膀胱过度活动症 追加 | 568 | 鹹壓願醖製選觸製廠範(壓壓簾鏇膚鑰選壓繭鹹) = 糧鑰繭襯願艱蓋顧鹽醖 鑰網繭築鬱製鏇顧餘餘 (築夢製艱糧遞廠鹹簾顧 ) 更多 | - | 2021-01-01 | ||
Placebo + Tamsulosin | 鹹壓願醖製選觸製廠範(壓壓簾鏇膚鑰選壓繭鹹) = 襯襯窪窪艱糧鬱鹽壓積 鑰網繭築鬱製鏇顧餘餘 (築夢製艱糧遞廠鹹簾顧 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用